What type of drug is Takhzyro?

Official answer

by Drugs.com

Key Points

Takhzyro (lanadelumab-flyo) is a human plasma kallikrein inhibitor and blocks a protein in your blood called kallikrein. Kallikrein regulates the production of bradykinin, a chemical that leads to inflammation (swelling) and hereditary angioedema (HAE) attacks.

Takhzyro (lanadelumab-flyo) was the first monoclonal antibody approved in the U.S. to prevent hereditary angioedema (HAE) types I and II. It is used in patients 2 years of age and older.

Takhzyro is given as a self-administered, subcutaneous (under the skin) injection, usually every 2 or 4 weeks. It is available as a single-dose prefilled syringe or as a single-dose vial.

Kalbitor (ecallantide) from Shire, is also an approved inhibitor of plasma kallikrein but is approved to treat (not prevent) attacks of hereditary angioedema in patients 12 years and older.

What is hereditary angioedema (HAE)?

Hereditary angioedema (HAE) is a rare genetic condition that occurs in people with low levels of certain proteins (C1-INH and C4) in their body. The low levels of proteins trigger excessive activation of the complement pathway and another protein called kallikrein. This increase in kallikrein activity results in too much bradykinin, the substance that causes HAE attacks.

HAE leads to severe, sudden swelling in the body caused by fluid that collects in deep layers of the skin, and may affect the stomach, limbs, face and throat.

What side effects occur with Takhzyro?

Important Takhzyro side effects

Seek emergency medical help or call 911 if you have signs of an allergic reaction to Takhzyro. Signs of an allergic reaction may include hives, rash, fast heartbeat, difficult breathing (wheezing), chest tightness, feeling light-headed or faint, swelling of your face, lips, tongue, or throat.

Common Takhzyro side effects may include:

headache

upper respiratory tract infection

rash

muscle aches

dizziness

diarrhea

pain, redness, or bruising where the injection was given.

Takhzyro has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking this drug in pregnancy or during breastfeeding.

This is not a complete list of side effects and others may occur. See more side effects in detail here.

This is not all the information you need to know about Takhzyro (lanadelumab-flyo) for safe and effective use. Review the full Takhzyro information here, and discuss this information and any questions you have with your doctor or other health care provider.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.